Literature DB >> 10952613

Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance.

V Kak1, S M Donabedian, M J Zervos, R Kariyama, H Kumon, J W Chow.   

Abstract

Enterococcus faecalis LC40 is an ampicillin-susceptible clinical isolate with high-level gentamicin resistance due to the aac(6')-Ie-aph(2")-Ia aminoglycoside resistance gene. The combination of ampicillin plus arbekacin reduced mean bacterial vegetation counts significantly more than ampicillin alone or ampicillin plus gentamicin in a rabbit model of aortic-valve endocarditis caused by E. faecalis LC40.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10952613      PMCID： PMC90103          DOI： 10.1128/AAC.44.9.2545-2546.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  In-vitro activity of the combination of ampicillin and arbekacin against high-level gentamicin-resistant enterococci.

Authors:  R Kariyama; H Kumon; L Chow; M J Zervos; T Takata; M Tabata; J W Chow
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

2.  A new high-level gentamicin resistance gene, aph(2'')-Id, in Enterococcus spp.

Authors:  S F Tsai; M J Zervos; D B Clewell; S M Donabedian; D F Sahm; J W Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  A Rodríguez; M V Vicente; T Olay
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

4.  High-level resistance to aminoglycosides: comparison of community and nosocomial fecal isolates of enterococci.

Authors:  T M Coque; R C Arduino; B E Murray
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

5.  Activity of ampicillin plus sulbactam against beta-lactamase producing enterococci in experimental endocarditis.

Authors:  L A Thal; J Vazquez; M B Perri; A Beckley; S Donabedian; G W Kaatz; J E Patterson; M J Zervos
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

6.  A novel gentamicin resistance gene in Enterococcus.

Authors:  J W Chow; M J Zervos; S A Lerner; L A Thal; S M Donabedian; D D Jaworski; S Tsai; K J Shaw; D B Clewell
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicillin-resistant Staphylococcus aureus.

Authors:  M Inoue; M Nonoyama; R Okamoto; T Ida
Journal:  Drugs Exp Clin Res       Date:  1994

8.  Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus.

Authors:  J M Hamilton-Miller; S Shah
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

9.  Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits.

Authors:  J Vazquez; M B Perri; L A Thal; S A Donabedian; M J Zervos
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

10.  Enzymatic 2'-N-acetylation of arbekacin and antibiotic activity of its product.

Authors:  K Hotta; C B Zhu; T Ogata; A Sunada; J Ishikawa; S Mizuno; Y Ikeda; S Kondo
Journal:  J Antibiot (Tokyo)       Date:  1996-05       Impact factor: 2.649
View more
  5 in total

1.  Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.

Authors:  Katsuhiro Miura; Masaru Nakagawa; Hiromichi Takahashi; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Masashi Sakagami; Shimon Ohtake; Sumiko Kobayashi; Atsuko Hojo; Daisuke Kurita; Yujin Kobayashi; Machiko Kusuda; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei
Journal:  Int J Hematol       Date:  2015-12-29       Impact factor: 2.490

2.  In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.

Authors:  Michael J Zapor; Melissa Barber; Amy Summers; George H Miller; Lee Ann Feeney; Lynn E Eberly; Glenn Wortmann
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

Review 3.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 4.  Clinical Usefulness of Arbekacin.

Authors:  Jae Hoon Lee; Chang-Seop Lee
Journal:  Infect Chemother       Date:  2016-03-31

5.  A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone.

Authors:  Ivone Jimenez-Toro; Carlos A Rodriguez; Andres F Zuluaga; Julian D Otalvaro; Omar Vesga
Journal:  PLoS One       Date:  2020-12-08       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.